Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Table 8 Major drug-drug interactions of the newer direct acting antivirals for hepatitis C

DAA	Co-administration should be avoided
Sofosbuvir	P-glycoprotein inducers
	Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin; antimycobacterials: Rifampin, rifabutin, rifapentin; St. John's wort; HIV drugs: Tipranavir/ritonavir
Simeprevir	Inhibitors or inducers of CYP3A4
	Antifungals: Fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole; Antibiotics: Clarithromycin, erythromycin, telithromycin; Dexamethasone; Cicapride; HIV drugs: Cobicistat, efavirenz, delavirdine, etravirine, nevirapine, ritonavir and any HIV protease inhibitor
	P-glycoprotein inducers
Daclatasvir	Strong inducers of CYP3A4 and/or P-glycoprotein
	e.g., phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, dexamethasone, St. John's wort; HIV drugs: darunavir, lopinavir, etravirine
Sofosbuvir/ledipasvir	P-glycoprotein inducers, rosuvastatin, simeprevir

DAA: Direct acting antiviral; HIV: Human immunodeficiency virus.